嵌合抗原受体 T 细胞（CAR T 细胞）可以在大部分复发/难治性淋巴瘤患者中诱导长期缓解。然而，人们对 CAR T 细胞治疗后患者的生活知之甚少。我们前瞻性地评估了淋巴瘤患者缓解后、白细胞去除术前、CAR T 细胞输注前以及之后 3、6 和 12 个月的多维恢复情况。使用经过验证的工具来测量淋巴瘤相关和全球健康相关的生活质量（HRQoL；癌症治疗-淋巴瘤功能评估[FACT-Lym]和EQ-5D-5L）、认知抱怨（FACT-Cognition）、疲劳（ FACIT-疲劳子量表）、心理状态（医院焦虑和抑郁量表、创伤后检查表量表）和性行为（关系和性行为量表）。缓解 12 个月后，我们还调查了身体、职业、性和一般生活状况。在第 3、6 和 12 个月时，分别有 53、35 和 23 名患者进行了评估。淋巴瘤相关 HRQoL 的改善在第 3、6 和 12 个月时具有临床相关性，相对于基线的平均变化为 10.9（95% 置信区间 [CI]：5.8；16.1）、12.2（95% CI：4.2；20.1）、分别为 11.72（95% CI：2.06；21.38）。总体 HRQoL、疲劳和焦虑的改善具有临床相关性，但随着时间的推移，20%-40% 的患者经历了持续疲劳、心理困扰和认知问题。 CAR T 细胞治疗超过 12 个月后，22 名可评估患者中有 81.8% 对日常生活感到满意。近一半患者的体力活动、职业、性和整体健康状况已恢复至诊断前水平。我们发现 CAR T 细胞治疗后 HRQoL 有所改善，包括焦虑、抑郁、性满意度和总体幸福感。然而，并非所有患者都能恢复“正常生活”。需要进一步研究来确定哪些患者面临生活质量受损的风险，以改善 CAR T 细胞输注后的恢复。© 2024 作者。约翰·威利 (John Wiley) 出版的 HemaSphere

Chimeric antigen receptor T cells (CAR T cells) can induce prolonged remission in a substantial subset of patients with relapse/refractory lymphoma. However, little is known about patients' life after CAR T-cell therapy. We prospectively assessed the multidimensional recovery of lymphoma patients in remission, before leukapheresis, before CAR T-cell infusion, and 3, 6, and 12 months thereafter. Validated tools were used to measure lymphoma-related and global health-related quality of life (HRQoL; Functional Assessment of Cancer Therapy-Lymphoma [FACT-Lym] and EQ-5D-5L), cognitive complaint (FACT-Cognition), fatigue (FACIT-Fatigue subscale), psychological status (Hospital Anxiety and Depression Scale, Post-Traumatic Check List Scale), and sexuality (Relationship and Sexuality Scale). Beyond 12 months of remission, we also surveyed physical, professional, sexual, and general life status. At 3, 6, and 12 months, 53, 35, and 23 patients were evaluable, respectively. Improvement in lymphoma-related HRQoL was clinically relevant at 3, 6, and 12 months with a mean change from baseline of 10.9 (95% confidence interval [CI]: 5.8; 16.1), 12.2 (95% CI: 4.2; 20.1), and 11.72 (95% CI: 2.06; 21.38), respectively. Improvement in global HRQoL, fatigue, and anxiety was clinically relevant, but 20%-40% of patients experienced persistent fatigue, psychological distress, and cognitive complaints over time. Beyond 12 months after CAR T cells, 81.8% of 22 evaluable patients were satisfied with their daily life. Physical activity, professional, sexual, and global well-being had returned to prediagnosis levels in nearly half of the patients. We found an improvement in HRQoL after CAR T-cell therapy including anxiety, depression, sexual satisfaction, and general well-being. However, not all patients recover a "normal life." Further research is needed to determine which patients are at risk of quality-of-life impairment to improve recovery after CAR T-cell infusion.© 2024 The Authors. HemaSphere published by John Wiley & Sons Ltd on behalf of European Hematology Association.